Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Clinical trial NCT06419179 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06419179
- Sponsor
- University of Cologne
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-09
- Primary completion
- 2026-09-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.